upload
National Cancer Institute
Sektör: Government; Health care
Number of terms: 6957
Number of blossaries: 0
Company Profile:
The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government's principal agency for ...
A radioactive isotope of cesium with an atomic mass of 139 and potential application in radiotherapy. Cesium Cs 137 is prevalent due to its spontaneous production, which occurs as a result of nuclear fission of other radioactive materials, such as uranium and plutonium. This radionuclide has a relatively long half-life, 30 years, and decays by emitting beta particles. Both Cs 137 and its metastable nuclear isomer, barium-137m, emit gamma radiation of moderate energy and so are used in sterilization procedures in the food industry or in hospital environments.
Industry:Pharmaceutical
A radioactive isotope of iodine, a nonmetallic element of the halogen group with an atomic mass of 123 and a half-life of 13. 2 hours with radioisotopic activity. Selectively accumulating in the thyroid tissue, iodine I 123 emits gamma rays that can be detected with gamma scintigraphy, allowing localization of thyroid tissue. This agent may be used as a tracer in whole body scintigraphy (WBS) to localize thyroid carcinoma metastases.
Industry:Pharmaceutical
A racemic mixture of the enantiomers of a synthetic alpha-lipoic lipoic acid analogue with potential chemopreventive and antineoplastic activities. Although the exact mechanism of action is unknown, alpha-lipoic acid analogue CPI-613 has been shown to inhibit metabolic and regulatory processes required for cell growth in solid tumors. Both enantiomers in the racemic mixture exhibit antineoplastic activity.
Industry:Pharmaceutical
A quinuclidinone derivative that targets the p53 protein with potential antineoplastic activity. The p53 activator APR-246 refolds/reactivates the p53 protein, which may lead to an induction of cell cycle arrest or apoptosis in tumor cells. This agent may work synergistically with other antineoplastic agents. p53, a tumor suppressor and transcription factor normally activated upon DNA damage, is mutated or absent in various cancer cell types and plays a key role in DNA repair and the induction of apoptosis.
Industry:Pharmaceutical
A quinolone derivative with potential antineoplastic activity. Semaxanib reversibly inhibits ATP binding to the tyrosine kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2), which may inhibit VEGF-stimulated endothelial cell migration and proliferation and reduce the tumor microvasculature. This agent also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells.
Industry:Pharmaceutical
A quinoline-3-carboxamide linomide analogue with antiangiogenic and potential antineoplastic activities. Tasquinimod has been shown to decrease blood vessel density but the exact mechanism of action is not known. This agent has also been shown to augment the antineoplastic effects of docetaxel and androgen ablation in a murine model of prostate cancer involving human prostate cancer xenografts.
Industry:Pharmaceutical
A quinidine alkaloid isolated from the bark of the cinchona tree. Quinine has many mechanisms of action, including reduction of oxygen intake and carbohydrate metabolism; disruption of DNA replication and transcription via DNA intercalation; and reduction of the excitability of muscle fibers via alteration of calcium distribution. This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents.
Industry:Pharmaceutical
A pyrrolotriazine-based compound and a pan inhibitor of receptor tyrosine kinases with potential antineoplastic activity. Pan HER/VEGFR2 receptor tyrosine kinase inhibitor BMS-690514 binds to human epidermal growth factor receptors (EGFR) 1, 2 and 4 (HER1, HER2 and HER4) and vascular endothelial growth factor receptor 1, 2 and 3 (VEGFR-1, -2 and -3), all of which are frequently overexpressed by a variety of tumor types. Binding of this agent to these receptors may result in the inhibition of tumor cell proliferation; the inhibition of endothelial cell migration and proliferation and angiogenesis; and tumor cell death.
Industry:Pharmaceutical
A pyrrolotriazine-based compound and a pan inhibitor of receptor tyrosine kinases with potential antineoplastic activity. Pan HER/VEGFR2 receptor tyrosine kinase inhibitor BMS-690154 binds to human epidermal growth factor receptors 1 and 2 (HER1, HER2) and vascular endothelial growth factor receptor 2 (VEGFR-2), all three of which are frequently overexpressed by a variety of tumor types. Binding of this agent to these receptors may result in the inhibition of tumor cell proliferation; the inhibition of endothelial cell migration and proliferation and angiogenesis; and tumor cell death.
Industry:Pharmaceutical
A pyrrolobenzodiazepine dimer with potential antineoplastic activity. SJG-136 binds to the minor groove of DNA and induces interstrand cross-links between two N-2 guanine positions, thereby inhibiting DNA replication and transcription. With a preference for binding to purine-GATC-pyrimidine sequences, SJG-136 adducts do not appear to be subject to p53-mediated DNA excision repair mechanisms.
Industry:Pharmaceutical